个人中心 - 老虎社区

Jordern5665

IP属地：未知

帖子 · 7帖子 · 7
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- Jordern5665Jordern5665
  ·2021-07-01
  Thanks
  1,854 评论
  点赞
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-24
  Nice
  非常抱歉，此主贴已删除
  2,127 评论
  点赞
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-24
  Nice
  A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year<blockquote>900美元的6.7英寸iPhone？分析师称苹果将于明年将该产品推向市场</blockquote>
  Apple Inc(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analy
  A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year<blockquote>900美元的6.7英寸iPhone？分析师称苹果将于明年将该产品推向市场</blockquote>
  2,002 评论
  1
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-24
  Apple is the best
  2,773 评论
  1
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-21
  Can invest this one ?
  Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme 在盘前交易中上涨超过 6%</blockquote>
  (June 21) Orphazyme rose more than 6% in premarket trading. What happened Shares of Orphazyme, a c
  Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme 在盘前交易中上涨超过 6%</blockquote>
  1,591 评论
  1
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-12
  [Cry]
  非常抱歉，此主贴已删除
  1,622 评论
  1
  分享
  举报
- Jordern5665Jordern5665
  ·2021-06-11
  [Cool]
  1,469 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3586338829912658","uuid":"3586338829912658","gmtCreate":1623247508144,"gmtModify":1623377522326,"name":"Jordern5665","pinyin":"jordern5665","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":8,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.61%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":151241265,"gmtCreate":1625096396357,"gmtModify":1631891683958,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"title":"","htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[{"img":"https://static.tigerbbs.com/d1cbb1a770832b5037394f9ae1894e5d","width":"750","height":"1238"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151241265","isVote":1,"tweetType":1,"viewCount":1854,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":128455071,"gmtCreate":1624528879993,"gmtModify":1631891683966,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"title":"","htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128455071","repostId":"2145043969","repostType":4,"isVote":1,"tweetType":1,"viewCount":2127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128456269,"gmtCreate":1624528839051,"gmtModify":1631891683978,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128456269","repostId":"1184361611","repostType":4,"repost":{"id":"1184361611","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1624526066,"share":"https://www.laohunote.com/m/news/1184361611?lang=zh_CN&edition=full","pubTime":"2021-06-24 17:14","market":"us","language":"en","title":"A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year<blockquote>900美元的6.7英寸iPhone？分析师称苹果将于明年将该产品推向市场</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184361611","media":"Benzinga Earnings","summary":"Apple Inc(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analy","content":"<p><b>Apple Inc</b>(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.</p><p><blockquote><b>苹果公司</b>分析师郭明𫓹表示，（纳斯达克股票代码：AAPL）将于明年推出两款屏幕更大的低端 iPhone。</blockquote></p><p> <b>What Happened:</b>&nbsp;Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will&nbsp;serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac.&nbsp;Both these models will also be available in the 6.1-inch screen size.</p><p><blockquote><b>发生了什么：</b>Kuo 说，苹果 2022 年下半年的产品线将包括两款配备 6.7 英寸屏幕的 iPhone 系列，其中一款将面向低端市场，另一款将面向高端市场，即 per9to5Mac。这两款机型也将提供 6.1 英寸屏幕尺寸。</blockquote></p><p> According to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.</p><p><blockquote>根据该报告，Kuo认为2022年的阵容将具有显示屏下指纹支持，并且将以大屏幕最实惠的价格提供，预计价格将低于900美元。</blockquote></p><p> The current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.</p><p><blockquote>目前的iPhone阵容包括6.7英寸的iPhone 12 Pro Max，售价为1099美元。郭表示，2022年的产品线可能会被命名为iPhone 14、iPhone 14 Pro和iPhone 14 Pro Max。</blockquote></p><p> <b>Why It Matters:</b>&nbsp;Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.</p><p><blockquote><b>为什么重要：</b>苹果去年推出的 iPhone 12 Pro Max 是其迄今为止最大的手机。据报道，该公司尚未公布的 2021 年产品阵容预计将采用与去年相同的变体，而重大变化要到明年才会揭晓。</blockquote></p><p> <b>Price Action:</b>&nbsp;Apple shares closed 0.2% lower at $133.70 on Wednesday.</p><p><blockquote><b>价格行为：</b>苹果股价周三收盘下跌 0.2%，至 133.70 美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e12ede45502bee1f416acaa08de1af92\" tg-width=\"661\" tg-height=\"250\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year<blockquote>900美元的6.7英寸iPhone？分析师称苹果将于明年将该产品推向市场</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA 6.7-Inch iPhone At $900? Analyst Says Apple Will Bring This Product To Market Next Year<blockquote>900美元的6.7英寸iPhone？分析师称苹果将于明年将该产品推向市场</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-06-24 17:14</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Apple Inc</b>(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.</p><p><blockquote><b>苹果公司</b>分析师郭明𫓹表示，（纳斯达克股票代码：AAPL）将于明年推出两款屏幕更大的低端 iPhone。</blockquote></p><p> <b>What Happened:</b>&nbsp;Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will&nbsp;serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac.&nbsp;Both these models will also be available in the 6.1-inch screen size.</p><p><blockquote><b>发生了什么：</b>Kuo 说，苹果 2022 年下半年的产品线将包括两款配备 6.7 英寸屏幕的 iPhone 系列，其中一款将面向低端市场，另一款将面向高端市场，即 per9to5Mac。这两款机型也将提供 6.1 英寸屏幕尺寸。</blockquote></p><p> According to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.</p><p><blockquote>根据该报告，Kuo认为2022年的阵容将具有显示屏下指纹支持，并且将以大屏幕最实惠的价格提供，预计价格将低于900美元。</blockquote></p><p> The current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.</p><p><blockquote>目前的iPhone阵容包括6.7英寸的iPhone 12 Pro Max，售价为1099美元。郭表示，2022年的产品线可能会被命名为iPhone 14、iPhone 14 Pro和iPhone 14 Pro Max。</blockquote></p><p> <b>Why It Matters:</b>&nbsp;Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.</p><p><blockquote><b>为什么重要：</b>苹果去年推出的 iPhone 12 Pro Max 是其迄今为止最大的手机。据报道，该公司尚未公布的 2021 年产品阵容预计将采用与去年相同的变体，而重大变化要到明年才会揭晓。</blockquote></p><p> <b>Price Action:</b>&nbsp;Apple shares closed 0.2% lower at $133.70 on Wednesday.</p><p><blockquote><b>价格行为：</b>苹果股价周三收盘下跌 0.2%，至 133.70 美元。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/e12ede45502bee1f416acaa08de1af92\" tg-width=\"661\" tg-height=\"250\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184361611","content_text":"Apple Inc(NASDAQ:AAPL) will launch two lower-end iPhones with larger screens next year, as per analyst Ming-Chi Kuo.\nWhat Happened: Apple’s lineup in the second half of 2022 will include two iPhone lines with 6.7-inch screens — one will serve the low-end market and another will cater to the premium one, Kuo said, as per9to5Mac. Both these models will also be available in the 6.1-inch screen size.\nAccording to the report, Kuo believes the 2022 lineup will have under-display fingerprint support and it will be available at the most affordable price point for a large screen and expected to be under $900.\nThe current iPhone lineup includes the 6.7-inch iPhone 12 Pro Max, which is priced at $1,099. Kuo said the 2022 lineup could be named iPhone 14, iPhone 14 Pro, and iPhone 14 Pro Max.\nWhy It Matters: Apple’s iPhone 12 Pro Max, launched last year, is its biggest phone to-date. The company’s yet-to-be-announced 2021 lineup is expected to sport the same variants as its predecessor from last year and the big changes will only be revealed next year, as per reports.\nPrice Action: Apple shares closed 0.2% lower at $133.70 on Wednesday.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2002,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128456309,"gmtCreate":1624528813301,"gmtModify":1631891683991,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"title":"","htmlText":"Apple is the best","listText":"Apple is the best","text":"Apple is the best","images":[{"img":"https://static.tigerbbs.com/036a9e33758775221b0e8c4dc3ad81d8","width":"1125","height":"3231"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128456309","isVote":1,"tweetType":1,"viewCount":2773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":167545445,"gmtCreate":1624279592087,"gmtModify":1631883985922,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"title":"","htmlText":"Can invest this one ?","listText":"Can invest this one ?","text":"Can invest this one ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167545445","repostId":"1184501396","repostType":2,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://www.laohunote.com/m/news/1184501396?lang=zh_CN&edition=full","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme 在盘前交易中上涨超过 6%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p><p><blockquote>（6月21日）Orphazyme在盘前交易中上涨超过6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么事</b></blockquote></p><p> Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p><p><blockquote>股份<b>奥尔法酶</b>在美国食品药品监督管理局 (FDA) 拒绝批准该公司主要候选人的申请后，一家临床阶段的生物制药公司受到了打击。投资者现在不确定这家生物技术公司何时可以销售获得批准的产品，截至美国东部时间中午 12:12，该股下跌 44.4%。上周五美国东部时间。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p><p><blockquote>FDA 去年 9 月开始审查 Orphazyme 的主要候选药物 arimoclomol 的申请，作为一种罕见但危及生命的疾病的潜在治疗方法，称为 Neimann-Pick 病 C 型 (NPC)。本月早些时候，Orphazyme 的股价上涨了 200% 以上，原因是预期从未到来的绿灯。</blockquote></p><p> Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p><p><blockquote>该机构没有做出arimoclomol的批准决定，而是以完整回复函（CRL）的形式要求提供更多信息。这让许多投资者感到震惊，他们刚刚接触复杂的药物开发世界，并预计会出现大规模的空头挤压。</blockquote></p><p> Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p><p><blockquote>许多机构投资者押注 Orphazyme，因为其主要候选药物未能在支撑该申请的关键研究中实现主要终点。Arimoclomol 也未能改善 FDA 特别要求的次要终点的患者评分。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在呢</b></blockquote></p><p> According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p><p><blockquote>据Orphazyme称，该公司需要进一步证实arimoclomol几乎达到的主要终点的有效性。为了满足 FDA 的要求，该公司很可能不得不进行一项新的关键研究。</blockquote></p><p> Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p><p><blockquote>一些股东仍然希望欧洲药品管理局不会像FDA那样严格。虽然FDA的欧洲同事过去在罕见疾病的治疗方面更加宽松，但arimoclomol可能不会向前推进，直到它产生一些令人信服的临床试验结果。</blockquote></p><p> Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p><p><blockquote>尽管缺乏明确的前进道路，这家总部位于丹麦的公司仍然拥有相当大的市值，按最近的价格计算，超过 5 亿美元。非理性的期望可能会使其保持较高水平，但对于任何临床阶段的生物技术公司 Orphazyme 的地位来说，这都太高了。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme 在盘前交易中上涨超过 6%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading<blockquote>Orphazyme 在盘前交易中上涨超过 6%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-21 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p><p><blockquote>（6月21日）Orphazyme在盘前交易中上涨超过6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么事</b></blockquote></p><p> Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p><p><blockquote>股份<b>奥尔法酶</b>在美国食品药品监督管理局 (FDA) 拒绝批准该公司主要候选人的申请后，一家临床阶段的生物制药公司受到了打击。投资者现在不确定这家生物技术公司何时可以销售获得批准的产品，截至美国东部时间中午 12:12，该股下跌 44.4%。上周五美国东部时间。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p><p><blockquote>FDA 去年 9 月开始审查 Orphazyme 的主要候选药物 arimoclomol 的申请，作为一种罕见但危及生命的疾病的潜在治疗方法，称为 Neimann-Pick 病 C 型 (NPC)。本月早些时候，Orphazyme 的股价上涨了 200% 以上，原因是预期从未到来的绿灯。</blockquote></p><p> Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p><p><blockquote>该机构没有做出arimoclomol的批准决定，而是以完整回复函（CRL）的形式要求提供更多信息。这让许多投资者感到震惊，他们刚刚接触复杂的药物开发世界，并预计会出现大规模的空头挤压。</blockquote></p><p> Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p><p><blockquote>许多机构投资者押注 Orphazyme，因为其主要候选药物未能在支撑该申请的关键研究中实现主要终点。Arimoclomol 也未能改善 FDA 特别要求的次要终点的患者评分。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在呢</b></blockquote></p><p> According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p><p><blockquote>据Orphazyme称，该公司需要进一步证实arimoclomol几乎达到的主要终点的有效性。为了满足 FDA 的要求，该公司很可能不得不进行一项新的关键研究。</blockquote></p><p> Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p><p><blockquote>一些股东仍然希望欧洲药品管理局不会像FDA那样严格。虽然FDA的欧洲同事过去在罕见疾病的治疗方面更加宽松，但arimoclomol可能不会向前推进，直到它产生一些令人信服的临床试验结果。</blockquote></p><p> Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p><p><blockquote>尽管缺乏明确的前进道路，这家总部位于丹麦的公司仍然拥有相当大的市值，按最近的价格计算，超过 5 亿美元。非理性的期望可能会使其保持较高水平，但对于任何临床阶段的生物技术公司 Orphazyme 的地位来说，这都太高了。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":1591,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188515238,"gmtCreate":1623454701824,"gmtModify":1631891684004,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"title":"","htmlText":"[Cry]&nbsp;","listText":"[Cry]&nbsp;","text":"[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188515238","repostId":"2142858202","repostType":4,"isVote":1,"tweetType":1,"viewCount":1622,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183450283,"gmtCreate":1623343136942,"gmtModify":1631891684017,"author":{"id":"3586338829912658","authorId":"3586338829912658","name":"Jordern5665","avatar":"https://static.tigerbbs.com/a1392e698d9d8446e6f5ac612e339304","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586338829912658","idStr":"3586338829912658"},"themes":[],"title":"","htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[{"img":"https://static.tigerbbs.com/5ea4062b862709c77427ce72a351be07","width":"1125","height":"3199"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/183450283","isVote":1,"tweetType":1,"viewCount":1469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}